Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 1, 2016, Pages 219-228.e9

  Weisser, Maren ^a   Demel, Uta M ^b,c   Stein, Stefan ^a   Chen Wichmann, Linping ^a   Touzot, Fabien ^d,e   Santilli, Giorgia ^f   Sujer, Stefanie ^b   Brendel, Christian ^a   Siler, Ulrich ^g   Cavazzana, Marina ^d,e   Thrasher, Adrian J ^f   Reichenbach, Janine ^g   Essers, Marieke A G ^b,c   Schwäble, Joachim ^a,h   Grez, Manuel ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Heidelberg Institute for Stem Cell Technology and Experimental Medicine HI STEM   (Germany)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e University of Sorbonne Paris la Cité   (France)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^h GOETHE UNIVERSITY   (Germany)

Author keywords

anakinra; cell cycle; Chronic granulomatous disease; competitive repopulation assay; dysfunctional hematopoiesis; engraftment defect; gene therapy; hematopoietic stem cell; hyperinflammation; IL 1

Indexed keywords

COLONY STIMULATING FACTOR 1; CXCL13 CHEMOKINE; CXCL9 CHEMOKINE; DEXAMETHASONE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 3; RANTES; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; AUTACOID; BIOLOGICAL MARKER; CYTOKINE;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MARROW CELL; CELL COMPARTMENTALIZATION; CELL COUNT; CELL CYCLE; CELL FUNCTION; CHILD; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; ENGRAFTMENT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL EXPANSION; X CHROMOSOME LINKED DISORDER; ADULT; ANIMAL; BIOLOGICAL MODEL; CASE CONTROL STUDY; CELL DIFFERENTIATION; CFU COUNTING; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GRAFT SURVIVAL; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOPHENOTYPING; METABOLISM; PHENOTYPE; PRESCHOOL CHILD; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BIOMARKERS; CASE-CONTROL STUDIES; CELL COUNT; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; COLONY-FORMING UNITS ASSAY; CYTOKINES; DISEASE MODELS, ANIMAL; GRAFT SURVIVAL; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PHENOTYPE; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84957073772     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.11.028     Document Type: Article

References (59)

1. 1 Roos, D., The genetic basis of chronic granulomatous disease. Immunol Rev 138 (1994), 121–157.
2. 2 Segal, A.W., The NADPH oxidase and chronic granulomatous disease. Mol Med Today 2 (1996), 129–135.
3. 3 Segal, B.H., Leto, T.L., Gallin, J.I., Malech, H.L., Holland, S.M., Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79 (2000), 170–200.
4. 4 Seger, R.A., Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 68 (2010), 334–340.
5. 5 Dinauer, M.C., Chronic granulomatous disease and other disorders of phagocyte function. Hematology Am Soc Hematol Educ Program 2005 (2005), 89–95.
6. 6 Bianchi, M., Niemiec, M.J., Siler, U., Urban, C.F., Reichenbach, J., Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J Allergy Clin Immunol 127 (2011), 1243–1252.e7.
7. 7 Morgenstern, D.E., Gifford, M.A., Li, L.L., Doerschuk, C.M., Dinauer, M.C., Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J Exp Med 185 (1997), 207–218.
8. 8 Rosenzweig, S.D., Inflammatory manifestations in chronic granulomatous disease (CGD). J Clin Immunol 28:suppl 1 (2008), S67–S72.
9. 9 Schappi, M.G., Jaquet, V., Belli, D.C., Krause, K.H., Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol 30 (2008), 255–271.
10. 10 Magnani, A., Brosselin, P., Beaute, J., de Vergnes, N., Mouy, R., Debre, M., et al. Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. J Allergy Clin Immunol 134 (2014), 655–662.e8.
11. 11 Petersen, J.E., Hiran, T.S., Goebel, W.S., Johnson, C., Murphy, R.C., Azmi, F.H., et al. Enhanced cutaneous inflammatory reactions to Aspergillus fumigatus in a murine model of chronic granulomatous disease. J Invest Dermatol 118 (2002), 424–429.
12. 12 Seger, R.A., Modern management of chronic granulomatous disease. Br J Haematol 140 (2008), 255–266.
13. 13 Gungor, T., Teira, P., Slatter, M., Stussi, G., Stepensky, P., Moshous, D., et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 383 (2013), 436–448.
14. 14 Oshrine, B., Morsheimer, M., Heimall, J., Bunin, N., Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease. Pediatr Blood Cancer 62 (2015), 359–361.
15. 15 Ahlin, A., Fasth, A., Chronic granulomatous disease—conventional treatment vs. hematopoietic stem cell transplantation: an update. Curr Opin Hematol 22 (2015), 41–45.
16. 16 Cole, T., Pearce, M.S., Cant, A.J., Cale, C.M., Goldblatt, D., Gennery, A.R., Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol 132 (2013), 1150–1155.
17. 17 Bianchi, M., Hakkim, A., Brinkmann, V., Siler, U., Seger, R.A., Zychlinsky, A., et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 114 (2009), 2619–2622.
18. 18 Kang, E.M., Choi, U., Theobald, N., Linton, G., Long Priel, D.A., Kuhns, D., et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 115 (2010), 783–791.
19. 19 Kang, H.J., Bartholomae, C.C., Paruzynski, A., Arens, A., Kim, S., Yu, S.S., et al. Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. Mol Ther 19 (2011), 2092–2101.
20. 20 Ott, M.G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12 (2006), 401–409.
21. 21 Stein, S., Ott, M.G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16 (2010), 198–204.
22. 22 Grez, M., Reichenbach, J., Schwable, J., Seger, R., Dinauer, M.C., Thrasher, A.J., Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 19 (2011), 28–35.
23. 23 Feldman, N., Rotter-Maskowitz, A., Okun, E., DAMPs as mediators of sterile inflammation in aging-related pathologies. Ageing Res Rev 24 (2015), 29–39.
24. 24 Geiger, H., Denkinger, M., Schirmbeck, R., Hematopoietic stem cell aging. Curr Opin Immunol 29 (2014), 86–92.
25. 25 Sauce, D., Larsen, M., Fastenackels, S., Pauchard, M., Ait-Mohand, H., Schneider, L., et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 117 (2011), 5142–5151.
26. 26 Makipour, S., Kanapuru, B., Ershler, W.B., Unexplained anemia in the elderly. Semin Hematol 45 (2008), 250–254.
27. 27 Dinarello, C.A., Simon, A., van der Meer, J.W., Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11 (2012), 633–652.
28. 28 Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9 (1998), 143–150.
29. 29 Panch, S.R., Yau, Y.Y., Kang, E.M., De Ravin, S.S., Malech, H.L., Leitman, S.F., Mobilization characteristics and strategies to improve hematopoietic progenitor cell mobilization and collection in patients with chronic granulomatous disease and severe combined immunodeficiency. Transfusion 55 (2015), 265–274.
30. 30 Rodriguez, S., Chora, A., Goumnerov, B., Mumaw, C., Goebel, W.S., Fernandez, L., et al. Dysfunctional expansion of hematopoietic stem cells and block of myeloid differentiation in lethal sepsis. Blood 114 (2009), 4064–4076.
31. 31 Zhang, P., Nelson, S., Bagby, G.J., Siggins, R. 2nd, Shellito, J.E., Welsh, D.A., The lineage-c-Kit+Sca-1+ cell response to Escherichia coli bacteremia in Balb/c mice. Stem Cells 26 (2008), 1778–1786.
32. 32 Singh, P., Yao, Y., Weliver, A., Broxmeyer, H.E., Hong, S.C., Chang, C.H., Vaccinia virus infection modulates the hematopoietic cell compartments in the bone marrow. Stem Cells 26 (2008), 1009–1016.
33. 33 Baldridge, M.T., King, K.Y., Goodell, M.A., Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 32 (2011), 57–65.
34. 34 Griseri, T., McKenzie, B.S., Schiering, C., Powrie, F., Dysregulated hematopoietic stem and progenitor cell activity promotes interleukin-23-driven chronic intestinal inflammation. Immunity 37 (2012), 1116–1129.
35. 35 Essers, M.A., Offner, S., Blanco-Bose, W.E., Waibler, Z., Kalinke, U., Duchosal, M.A., et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458 (2009), 904–908.
36. 36 Essers, M.A., Trumpp, A., Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 4 (2010), 443–450.
37. 37 Chen, G.Y., Nunez, G., Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10 (2010), 826–837.
38. 38 Henao-Mejia, J., Elinav, E., Strowig, T., Flavell, R.A., Inflammasomes: far beyond inflammation. Nat Immunol 13 (2012), 321–324.
39. 39 Strowig, T., Henao-Mejia, J., Elinav, E., Flavell, R., Inflammasomes in health and disease. Nature 481 (2012), 278–286.
40. 40 Brown, J.R., Goldblatt, D., Buddle, J., Morton, L., Thrasher, A.J., Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol 73 (2003), 591–599.
41. 41 Meissner, F., Seger, R.A., Moshous, D., Fischer, A., Reichenbach, J., Zychlinsky, A., Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 116 (2010), 1570–1573.
42. 42 van de Veerdonk, F.L., Smeekens, S.P., Joosten, L.A., Kullberg, B.J., Dinarello, C.A., van der Meer, J.W., et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A 107 (2010), 3030–3033.
43. 43 Segal, B.H., Han, W., Bushey, J.J., Joo, M., Bhatti, Z., Feminella, J., et al. NADPH oxidase limits innate immune responses in the lungs in mice. PLoS One, 5, 2010, e9631.
44. 44 Rubartelli, A., Redox control of NLRP3 inflammasome activation in health and disease. J Leukoc Biol 92 (2012), 951–958.
45. 45 Zeng, M.Y., Pham, D., Bagaitkar, J., Liu, J., Otero, K., Shan, M., et al. An efferocytosis-induced, IL-4-dependent macrophage-iNKT cell circuit suppresses sterile inflammation and is defective in murine CGD. Blood 121 (2013), 3473–3483.
46. 46 de Luca, A., Smeekens, S.P., Casagrande, A., Iannitti, R., Conway, K.L., Gresnigt, M.S., et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci U S A 111 (2014), 3526–3531.
47. 47 Baroja-Mazo, A., Martin-Sanchez, F., Gomez, A.I., Martinez, C.M., Amores-Iniesta, J., Compan, V., et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 15 (2014), 738–748.
48. 48 Geering, B., Stoeckle, C., Conus, S., Simon, H.U., Living and dying for inflammation: neutrophils, eosinophils, basophils. Trends Immunol 34 (2013), 398–409.
49. 49 Brown, K.L., Bylund, J., MacDonald, K.L., Song-Zhao, G.X., Elliott, M.R., Falsafi, R., et al. ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease. Clin Immunol 129 (2008), 90–102.
50. 50 Fibbe, W.E., Hamilton, M.S., Laterveer, L.L., Kibbelaar, R.E., Falkenburg, J.H., Visser, J.W., et al. Sustained engraftment of mice transplanted with IL-1-primed blood-derived stem cells. J Immunol 148 (1992), 417–421.
51. 51 Garlanda, C., Dinarello, C.A., Mantovani, A., The interleukin-1 family: back to the future. Immunity 39 (2013), 1003–1018.
52. 52 McKinstry, W.J., Li, C.L., Rasko, J.E., Nicola, N.A., Johnson, G.R., Metcalf, D., Cytokine receptor expression on hematopoietic stem and progenitor cells. Blood 89 (1997), 65–71.
53. 53 Yang, J., Ikezoe, T., Nishioka, C., Nobumoto, A., Yokoyama, A., IL-1beta inhibits self-renewal capacity of dormant CD34(+)/CD38(-) acute myelogenous leukemia cells in vitro and in vivo. Int J Cancer 133 (2013), 1967–1981.
54. 54 Yonemura, Y., Ku, H., Hirayama, F., Souza, L.M., Ogawa, M., Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc Natl Acad Sci U S A 93 (1996), 4040–4044.
55. 55 Nagamachi, A., Nakata, Y., Ueda, T., Yamasaki, N., Ebihara, Y., Tsuji, K., et al. Acquired deficiency of A20 results in rapid apoptosis, systemic inflammation, and abnormal hematopoietic stem cell function. PLoS One, 9, 2014, e87425.
56. 56 Hahn, K.J., Ho, N., Yockey, L., Kreuzberg, S., Daub, J., Rump, A., et al. Treatment with anakinra, a recombinant IL-1 receptor antagonist, unlikely to induce lasting remission in patients with CGD colitis. Am J Gastroenterol 110 (2015), 938–939.
57. Santilli, G., Almarza, E., Brendel, C., Choi, U., Beilin, C., Blundell, M.P., et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 19 (2011), 122–132.
58. Brendel, C., Hanseler, W., Wohlgensinger, V., Brendel, C., Hanseler, W., Wohlgensinger, V., et al. Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy, et al. Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy. Hum Gene Ther Methods 24 (2013), 151–159.
59. Challen, G.A., Boles, N., Lin, K.K., Goodell, M.A., Mouse hematopoietic stem cell identification and analysis. Cytometry A 75 (2009), 14–24.